SECTION 05 REFERENCES CONTINUED REFERENCES
https://news.cancerresearchuk.org/2018/05/29/science-surgery-whats-the-difference-betw ganised in the same way. NHS England (2016) Improving Outcomes Through Personalised Medicine. Available at h ised-medicine.pdf NHS England: NHS Genomic Medicine Service. Available at https://www.england.nhs.uk/g NHS Scotland: Genetic and molecular pathology laboratories: https://www.england.nhs.uk NHS UK Genetic and genomic testing Available at https://www.nhs.uk/conditions/genetic-a NICE Technology Appraisal guidance TA644: Entrectinib for treating NTRK fusion-positive ance/ta644 NICE Technology Appraisal guidance TA630: Larotrectinib for treating NTRK fusion-positiv ance/ta630) Northern Ireland Genomics Centre: Queen’s University Belfast : https://www.qub.ac.uk/res The Personalised Medicine Coalition (PMC) - The Personalized Medicine Report. Availabl PMC_The_Personalized_Medicine_Report_Opportunity_Challenges_and_the_Future.pdf Sansone et al (2019) Specific and Non-Specific Biomarkers in Neuroendocrine Gastroente Sheridan, Harris & Woolf (2004) Shared decision making about screening and chemoprev Journal of Preventative Medicine: https://pubmed.ncbi.nlm.nih.gov/14700714/ Sigal et al (2018) Comprehensive genomic profiling identifies novel NTRK fusions in neuro the findings were in neuroendocrine carcinomas) Sigal et al (2018) Comprehensive genomic profiling identifies novel NTRK fusions in neuro the findings were in neuroendocrine carcinomas) Source: NHS UK website: https://www.nhs.uk/conditions/genetic-and-genomic-testing/
Made with FlippingBook - Share PDF online